People In Brief
This article was originally published in The Gray Sheet
Executive Summary
Biomet's new CFO: Daniel Florin, Boston Scientific's VP and corporate controller for the past six years, will join Biomet June 5 as CFO. He fills the hole left at Biomet by Gregory Hartman's departure March 30 as a result of stock option investigations (1"The Gray Sheet" April 9, 2007, In Brief). Florin began working at Boston Scientific in 1995. Prior to that, he spent five years serving in financial positions at C.R. Bard. J. Pat Richardson, who is acting as interim CFO at Biomet, will continue as the firm's VP-finance...
You may also be interested in...
Biomet execs resign
CFO Gregory Hartman and Executive VP Daniel Hann announce their retirement March 30 after preliminary findings of an investigation into Biomet's stock option granting procedures over the last 11 years revealed improper accounting. The internal report found that most of the stock options the company issued between 1996 and 2006 were "opportunistically misdated" to take advantage of a lower exercise price and that Hann and Hartman "were or should have been aware of certain accounting and legal ramifications" of the misdating. Biomet, which is in the process of going private, will restate financial statements for 2006 (1"The Gray Sheet" Jan. 1, 2007, p. 6). The firm says the restatements will include a noncash compensation cost of about $50 million between 1996 and 2006. Effective April 11, J. Pat Richardson, former VP-finance at Johnson & Johnson/Cordis, will serve as interim CFO and treasurer until permanent replacements are hired. Separately, the company names former Worldwide President of Cordis Endovascular, Glen Kashuba, president of Biomet Trauma and Biomet Spine on April 4, replacing Charles Niemier, who becomes senior VP-Biomet International and corporate relations...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.